As of today, there are no large-scale, double-blind, placebo-controlled human trials specifically investigating BPC 157 for herniated discs
[1] [2] This medication works by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptyingan effect that is most pronounced after initial doses and may attenuate over timeleading to reduced appetite and caloric intake
However, oral glutathione supplementation is limited by poor bioavailability due to gastrointestinal degradation and low membrane permeability
ARA-290, also known as cibinetide, holds FDA Orphan Drug designation for sarcoidosis-associated neuropathy, but it is not yet approved as a prescription medication
Thank you, Melissa, for giving our IV therapy treatments